The European Commission’s FP7 Programme to Boost the Life Science R&D Funding in Europe, Finds Frost & Sullivan

LONDON, April 27, 2010 – Europe is moving towards becoming a knowledge-based economy. Keeping in
line with this objective, the European commission has instituted the
Framework 7 (FP7) programme. Launched to support the re-launched Lisbon
strategy, FP7 focuses on research themes rather than the framework programmes
of the past. It has been designed to meet some of the [...]

MarketsandMarkets: Global OLED Market Worth US$2.2 Billion by 2014

DALLAS, Texas, April 27, 2010 – According to a new market research report, 'Opportunities in the Global
OLED Display Market', published by MarketsandMarkets
(www.marketsandmarkets.com), the global OLED product market is
expected to be worth US$2.2 billion by 2014, growing at a CAGR of 24.7% from
2009 to 2014. The Asia-Pacific market is expected to account for nearly 90%
of [...]

ASP Sterrad Technology Approved by AFSSAPS for Total Inactivation of Prions

French Health Products Safety Agency AFSSAPS Approves STERRAD(R) Hydrogen Peroxide Gas Plasma Technology for Total Inactivation of Protein-based Infectious Agents Linked to Fatal Brain Diseases

PARIS, April 27, 2010 – Advanced Sterilization Products (ASP) announced today that the French
Health Products Safety Agency, AFSSAPS, will approve the low-temperature
hydrogen peroxide gas plasma STERRAD(R) NX(TM) and the STERRAD(R) [...]

Kiadis Pharma Provides ATIR(TM) Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality

FDA Grants ATIR(TM) Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality

AMSTERDAM, April 28, 2010 – Kiadis Pharma today provided an update on its cell therapy product
ATIR(TM) developed for mismatched bone marrow transplants. ATIR(TM) continues
to show excellent clinical results in patients who received a mismatched bone
marrow transplantation from a [...]

Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen

DUBLIN, April 27, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that it has received a Paragraph IV
Notice Letter from Anchen Pharmaceuticals, Inc. ("Anchen") advising of the
filing of an Abbreviated New Drug Application ("ANDA") for a generic version
of Shire's 1 mg, 2 mg, 3 mg, and 4 mg guanfacine [...]

Torchmark Corporation Reports First Quarter 2010 Results

MCKINNEY, Texas, April 27, 2010 – Torchmark Corporation (NYSE: TMK) reported today that for the quarter
ended March 31, 2010, net income was US$1.46 per share compared with US$0.91
per share for the year-ago quarter. Net operating income for the quarter was
US$1.52 per share, a 2% increase compared with US$1.49 per share for the
year-ago quarter.

[...]